Pancreatic Cancer Research

ResearcherUniversity of PisaActive in the last 2 years

Daniele Campa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-3220-9944; OpenAlex author ID A5070690527, A5105756717. Sources: OpenAlex.

Their work

Papers
73 (first author 4, last author 25)
Trials
0
Grants
0
Labs led
1
Collaborators
148
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 3 papers · 2014: 2 papers · 2015: 2 papers · 2016: 3 papers · 2017: 2 papers · 2018: 3 papers · 2019: 5 papers · 2020: 4 papers · 2021: 8 papers · 2022: 2 papers · 2023: 7 papers · 2024: 6 papers · 2025: 19 papers · 2026: 6 papers

Papers 50 of 73

  1. Immune Markers and Risk of Pancreatic Cancer in the European EPIC Cohort. Co-author DOI 10.1002/ijc.70581↗
  2. Metamorphoses in pancreatic cancer precursors: the role of simple mucinous cysts†. First author DOI 10.1002/path.6493↗
  3. Non-coding RNAs as biomarkers and therapeutic targets in pancreatic cancer: Clinical implications and translational perspectives. Co-author DOI 10.1016/j.biopha.2026.119394↗
  4. Polygenic scores for risk of pancreatic ductal adenocarcinoma: evaluation of novel and published models. Co-author DOI 10.1038/s41698-026-01479-x↗
  5. Predicting pancreatic cancer in high-risk individuals and in the general population: how long is the road yet? Co-author DOI 10.17235/reed.2026.12183/2026↗
  6. Novel Genetic Risk Loci for Pancreatic Ductal Adenocarcinoma Identified in a Genome-wide Study of African Ancestry Individuals Co-author DOI 10.64898/2026.04.21.26351329↗
  7. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional… Co-author DOI 10.1002/ijc.35196↗
  8. Evaluating Sex Disparity in Pancreatic Ductal Adenocarcinoma Risk in the UK Biobank Cohort. Last author DOI 10.1002/ueg2.70102↗
  9. Genetic landscape for screening and early diagnosis of pancreatic ductal adenocarcinoma: is there a signature? Co-author DOI 10.1016/j.bpg.2025.101988↗
  10. Explainable machine learning identifies a polygenic risk score as a key predictor of pancreatic cancer risk in the UK Biobank. Last author DOI 10.1016/j.dld.2024.11.010↗
  11. Author's Reply: Comment on "Analysis of exposome and genetic variability suggests stress as a major contributor for development of pancreatic ductal adenocarci… Co-author DOI 10.1016/j.dld.2024.12.025↗
  12. Multi-omic markers of intraductal papillary mucinous neoplasms progression into pancreatic cancer. Last author DOI 10.1016/j.semcancer.2024.12.005↗
  13. Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications. Co-author DOI 10.1016/j.semcancer.2025.01.003↗
  14. Biomarkers, omics and artificial intelligence for early detection of pancreatic cancer. Co-author DOI 10.1016/j.semcancer.2025.02.009↗
  15. The relationship of the microbiome, associated metabolites and the gut barrier with pancreatic cancer. Co-author DOI 10.1016/j.semcancer.2025.03.002↗
  16. From classical approaches to artificial intelligence, old and new tools for PDAC risk stratification and prediction. Co-author DOI 10.1016/j.semcancer.2025.03.004↗
  17. Targeting pancreatic cancer screening by identification of pathogenic variants of BRCA2/ BRCA1 in healthy individuals who have no known family history of pancr… Co-author DOI 10.1016/j.semcancer.2025.05.001↗
  18. The exposome and pancreatic cancer, lifestyle and environmental risk factors for PDAC. Co-author DOI 10.1016/j.semcancer.2025.05.004↗
  19. Genomic instability, DNA damage response and telomere homeostasis in pancreatic cancer. Co-author DOI 10.1016/j.semcancer.2025.05.005↗
  20. Long-term recurrence of PDAC after resection for IPMN: A narrative review of the literature on clinical and biologic predictors. Co-author DOI 10.1016/j.semcancer.2025.06.001↗
  21. Therapeutic pancreatic cancer biomarkers and pharmacogenetics. Co-author DOI 10.1016/j.semcancer.2025.08.002↗
  22. Allelic effects on KLHL17 expression underlie a pancreatic cancer genome-wide association signal at chr1p36.33. Co-author DOI 10.1038/s41467-025-59109-2↗
  23. Long or short? Telomere length and pancreatic cancer and its precursor lesions, a narrative review. Co-author DOI 10.1093/mutage/gead034↗
  24. A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma. Last author DOI 10.1093/mutage/geae012↗
  25. Sex Disparities and Female Reproductive and Hormonal Factors Associated with Risk of Pancreatic Cancer in the European Prospective Investigation into Cancer an… Co-author DOI 10.3390/cancers17142275↗
  26. Potential association between PSCA rs2976395 functional variant and pancreatic cancer risk. Last author DOI 10.1002/ijc.35046↗
  27. Analysis of exposome and genetic variability suggests stress as a major contributor for development of pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.dld.2023.10.015↗
  28. Genetically predicted gut bacteria, circulating bacteria-associated metabolites and pancreatic ductal adenocarcinoma: a Mendelian randomisation study. Last author DOI 10.1038/s41598-024-77431-5↗
  29. Publisher Correction: Genetically predicted gut bacteria, circulating bacteria-associated metabolites and pancreatic ductal adenocarcinoma: a Mendelian randomi… Last author DOI 10.1038/s41598-024-83618-7↗
  30. Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk. Co-author DOI 10.1186/s40246-024-00576-x↗
  31. Physical Activity, Sedentary Behavior, and Pancreatic Cancer Risk: A Mendelian Randomization Study. Last author DOI 10.1210/jendso/bvae017↗
  32. Association between a polymorphic variant in the CDKN2B-AS1/ANRIL gene and pancreatic cancer risk. Last author DOI 10.1002/ijc.34383↗
  33. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  34. Genetic and non-genetic risk factors for early-onset pancreatic cancer. Last author DOI 10.1016/j.dld.2023.02.023↗
  35. A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarc… Last author DOI 10.1093/carcin/bgad056↗
  36. Polymorphic variants involved in methylation regulation: a strategy to discover risk loci for pancreatic ductal adenocarcinoma. Last author DOI 10.1136/jmg-2022-108910↗
  37. Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians. Last author DOI 10.1186/s40659-023-00457-y↗
  38. Role of pancreatic ductal adenocarcinoma risk factors in intraductal papillary mucinous neoplasm progression. Last author DOI 10.3389/fonc.2023.1172606↗
  39. Germline genetic variability in pancreatic cancer risk and prognosis. Last author DOI 10.1016/j.semcancer.2020.08.003↗
  40. Common variability in oestrogen-related genes and pancreatic ductal adenocarcinoma risk in women. Last author DOI 10.1038/s41598-022-22973-9↗
  41. Genome-wide scan of long noncoding RNA single nucleotide polymorphisms and pancreatic cancer susceptibility. Last author DOI 10.1002/ijc.33475↗
  42. Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival. Co-author DOI 10.1038/s41598-021-87130-0↗
  43. Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. Last author DOI 10.1093/carcin/bgab057↗
  44. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. Last author DOI 10.1136/jmedgenet-2020-106961↗
  45. Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3. Co-author DOI 10.1158/0008-5472.can-20-3267↗
  46. Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Last author DOI 10.1158/1055-9965.epi-21-0353↗
  47. Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. Co-author DOI 10.3389/fgene.2021.693933↗
  48. Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. Co-author DOI 10.3389/fonc.2021.771312↗
  49. Genome-wide association study identifies an early onset pancreatic cancer risk locus. Co-author DOI 10.1002/ijc.33004↗
  50. Mendelian randomisation study of the effects of known and putative risk factors on pancreatic cancer. Co-author DOI 10.1136/jmedgenet-2019-106200↗

Closest collaborators

The 25 strongest of 148 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Manuel Gentiluomo · 21 shared papers, 2019–2025 · strength 3.76
  2. Federico Canzian · 28 shared papers, 2011–2026 · strength 3.47
  3. Cosmeri Rizzato · 18 shared papers, 2011–2026 · strength 3.16
  4. Riccardo Farinella · 13 shared papers, 2023–2025 · strength 2.71
  5. Giulia Peduzzi · 12 shared papers, 2019–2025 · strength 2.57
  6. Gabriele Capurso · 16 shared papers, 2013–2025 · strength 1.67
  7. Chiara Corradi · 6 shared papers, 2021–2025 · strength 1.17
  8. David J. Hughes · 6 shared papers, 2017–2026 · strength 1.13
  9. Neil Daniel · 5 shared papers, 2024–2026 · strength 1.09
  10. Pavel Souček · 11 shared papers, 2013–2025 · strength 1.02
  11. William Greenhalf · 8 shared papers, 2011–2026 · strength 1.00
  12. Eithne Costello · 9 shared papers, 2011–2025 · strength 0.97
  13. Lívia Archibugi · 6 shared papers, 2018–2025 · strength 0.91
  14. Julie Earl · 3 shared papers, 2025–2026 · strength 0.85
  15. Stefano Crippa · 3 shared papers, 2023–2026 · strength 0.83
  16. Francesca Tavano · 10 shared papers, 2013–2025 · strength 0.81
  17. Pavel Vodička · 9 shared papers, 2013–2025 · strength 0.80
  18. Luca Morelli · 6 shared papers, 2020–2025 · strength 0.76
  19. Stefano Landi · 9 shared papers, 2013–2025 · strength 0.71
  20. Paolo Riccardo Camisa · 2 shared papers, 2025–2026 · strength 0.68
  21. Juan Sáinz · 3 shared papers, 2025–2026 · strength 0.67
  22. Beatrice Mohelníková-Duchoňová · 8 shared papers, 2013–2025 · strength 0.67
  23. Ľudmila Vodičková · 7 shared papers, 2013–2025 · strength 0.63
  24. Verena Andrea Katzke · 6 shared papers, 2014–2026 · strength 0.61
  25. Pinar Uysal Onganer · 3 shared papers, 2025–2026 · strength 0.60

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.